Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • HLA Today
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Research and News
    • Browse Research
      • Pre-transplant blinatumomab reduces MRD, time to HCT for pediatric patients with B-ALL
      • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL
      • Cryopreservation of allogenic HCT grafts does not adversely impact early post-HCT outcomes
      • Precision medicine initiative uses whole genome sequencing to identify novel prognostic signatures and the impact of genomic subgroups in MDS allogeneic HCT patients
    • Browse News
    • About Our Research
    • Transplant Enews
      • Advances in Transplant Enews
      • Resource Connection Enews
  • Resources and Education
    • HCT Presentation Slides
      • Hemaglobinopathies, Transplant Consultation Timing Guidelines
      • Myeloproliferative Neoplasms (MPN), Transplant Consultation Timing Guidelines
    • Patient Resources
    • Financial Resources
    • Materials Catalog
    • Obstetrician Resources
    • Education Catalog
      • Sickle Cell Disease: Exploring treatment options and psychosocial care
      • Continuing Education Discontinuation
      • Building Yourself From The Ground Up
      • Advances in HCT Over Time
    • Technique Video
    • Umbilical Cord Blood Collection Training for Public Donation
  • Early Complications
  • Vaccinations
  • Long-Term Care Guidelines
  • Chronic GVHD
  • Post-Transplant Guidelines

Long-Term Care Guidelines

  • Pediatric Considerations
Research Spotlight
  • Haploidentical HCT is viable alternative to matched sibling HCT in patients with AML in CR1

    July 2019

  • Gait speed can predict survival, hospital use in older patients with blood cancers

    July 2019

  • Continued vigilance needed to prevent infections for HCT recipients

    January 2019

  • Post-Transplant Care
  • Long-Term Care Guidelines
  • Pediatric Considerations
  • Email
  • Print This Page

Related Resources

  • CME: Pediatric Survivors after HCT
  • HCT Guidelines App
  • Post-HCT Vaccinations
  • Chronic GVHD

 

Patient Resources

  • Post-Bone Marrow Transplant Care Guidelines
  • Super Sam vs. the Marrow Monsters (Pediatric Video)
  • Living Now: Parent Caregiver Issue

Pediatric-Specific Screening and Prevention Post HCT

Pediatric hematopoietic cell transplant (HCT) patients have unique post-transplant screening needs caused by pre-transplantation conditioning including total body irradiation (TBI) and chemotherapy.

In addition to screening recommendations for all HCT recipients, pediatric patients have special considerations for the nervous system, endocrine system and oral health. [1]
View Long-Term Care Guidelines (PDF).

Nervous System

Children exposed to TBI are also at risk for developmental delays. Evaluation for cognitive developmental milestones should be performed at least annually in pediatric patients.

Endocrine System

Growth retardation is frequent in transplanted pediatric patients receiving TBI and many children receiving transplants will have markedly reduced growth rates for two years post-transplant. Similarly, growth hormone deficiency is also common.
Hypothyroidism can occur in patients receiving irradiation to the head. Transplant recipients with hypothyroidism should receive thyroxine. [2]

Oral Health

In pediatric transplant patients, there is the potential for radiation to interfere with the development of the teeth and face. Underdevelopment of the mandible is of particular concern. Changes in dental and facial development are most severe in children under the age of seven when transplanted. Annual oral evaluation for tooth development is recommended.

Post-Transplant Care Guidelines

We offer guidelines for evaluations at 6 months and 12 months after transplant, then annually thereafter. Specific measures for pediatric patients are included.

Access HCT Guidelines for Clinicians

  • Access interactive tool  for a customizable list of screening recommendations
  • Download Post-HCT Care Guidelines (PDF)
  • Order print version or download the HCT Guidelines mobile app

Access Patient Post-Transplant Care Guidelines

  • Post-bone marrow transplant guidelines

Children's Oncology Group Guidelines

The Children's Oncology Group (COG) has developed Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, which are available at survivorshipguidelines.org. They include recommended long-term care for recipients of autologous or allogeneic HCT for malignant and non-malignant diseases, organized by organ systems that include accompanying evidence grades. An overview of the COG guidelines focusing on the long-term care of transplant recipients has also been published in Biology of Blood and Marrow Transplantation. [3]


References

  1. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation; Center for International Blood and Marrow Transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation (ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ), East Mediterranean Blood and Marrow Transplantation Group (EMBMT) and Sociedade Brasileira de Transplante de Medula Ossea (SBTMO). Co-published in Biol Blood Marrow Transplant, 2012, 18(3): 348-371; Bone Marrow Transplant, 2012, 47(3): 337-341; and Hematol Oncol Stem Cell Ther, 2012, 5(1): 1-30. Access
  2. Sanders JE. Growth and development after hematopoietic cell transplant in children. Bone Marrow Transplant. 2008; 41(2): 223-227. Access
  3. Chow EJ, Anderson L, Baker KS, et al. Late effects surveillance recommendations among survivors of childhood hematopoietic cell transplantation: A Children's Oncology Group Report. Biol Blood Marrow Transplant. 2016; 22(5): 782-795. Access
  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Transplant Indications and Outcomes

  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources and Education

  • HCT Presentation Slides
  • Patient Resources
  • Financial Resources
  • Materials Catalog
  • Obstetrician Resources
  • Education Catalog
  • Technique Video
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2022 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright